ZMB Member Martin Schuler

ZMB Member
Martin Schuler

Next ZMB-Member
Martin Schuler portrait
© UKE

Prof. Dr. Martin Schuler

University Hospital Essen
Hufelandstraße 55
45147 Essen

Research Overview

Clinical research

  • Biomarker-stratified early clinical drug development
  • Immuno-oncology
  • Lung cancer and thoracic oncology

Translational and clinical-related basic research

  • Mechanisms of drug resistance and immune evasion
  • Mechanisms of tumor progression and metastasis
  • Lung cancer biology

Read more

Selected Publications

    Journal articles

  • Felip, E.; Cho, B.C.; Gutiérrez, V.; Alip, A.; Besse, B.; Lu, S.; Spira, A.I.; Girard, N.; Califano, R.; Gadgeel, S.M.; Yang, J.C.-H.; Yamamoto, S.; Azuma, K.; Kim, Y.J.; Lee, K.-H.; Danchaivijitr, P.; Ferreira, C.G.; Cheng, Y.; Sendur, M.A.N.; Chang, G.-C.; Wang, C.-C.; Prabhash, K.; Shinno, Y.; Stroyakovskiy, D.; Paz-Ares, L.; Rodriguez-Cid, J.R.; Martin, C.; Campelo, M.R.G.; Hayashi, H.; Nguyen, D.; Tomasini, P.; Gottfried, M.; Dooms, C.; Passaro, A.; Schuler, Martin; Gelatti, A.C.Z.; Owen, S.; Perdrizet, K.; Ou, S.-H.I.; Curtin, J.C.; Zhang, J.; Gormley, M.; Sun, T.; Panchal, A.; Ennis, M.; Fennema, E.; Daksh, M.; Sethi, S.; Bauml, J.M.; Lee, S.-H.
    Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease : a secondary analysis from MARIPOSA
    In: Annals of Oncology Vol. 35 (2024) Nr. 9, pp. 805 - 816
  • George, Julie; Maas, Lukas; Abedpour, Nima; Cartolano, Maria; Kaiser, Laura; Fischer, Rieke N.; Scheel, Andreas H.; Weber, Jan-Philipp; Hellmich, Martin; Bosco, Graziella; Volz, Caroline; Mueller, Christian; Dahmen, Ilona; John, Felix; Alves, Cleidson Padua; Werr, Lisa; Panse, Jens Peter; Kirschner, Martin; Engel-Riedel, Walburga; Jürgens, Jessica; Stoelben, Erich; Brockmann, Michael; Grau, Stefan; Sebastian, Martin; Stratmann, Jan A.; Kern, Jens; Hummel, Horst-Dieter; Hegedüs, Balazs; Schuler, Martin; Plönes, Till; Aigner, Clemens; Elter, Thomas; Toepelt, Karin; Ko, Yon-Dschun; Kurz, Sylke; Grohé, Christian; Serke, Monika; Höpker, Katja; Hagmeyer, Lars; Doerr, Fabian; Hekmath, Khosro; Strapatsas, Judith; Kambartel, Karl-Otto; Chakupurakal, Geothy; Busch, Annette; Bauernfeind, Franz-Georg; Griesinger, Frank; Luers, Anne; Dirks, Wiebke; Wiewrodt, Rainer; Luecke, Andrea; Rodermann, Ernst; Diel, Andreas; Hagen, Volker; Severin, Kai; Ullrich, Roland T.; Reinhardt, Hans Christian; Quaas, Alexander; Bogus, Magdalena; Courts, Cornelius; Nürnberg, Peter; Becker, Kerstin; Achter, Viktor; Büttner, Reinhard; Wolf, Jürgen; Peifer, Martin; Thomas, Roman K.
    Evolutionary trajectories of small cell lung cancer under therapy
    In: Nature Vol. 627 (2024) Nr. 8005, pp. 880 - 889
  • Pant, Shubham; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A.; Massard, Christophe; Minchom, Anna; Lugowska, Iwona; Carranza, Omar; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Stuyckens, Kim; Crow, Lauren; Najmi, Saltanat; Hammond, Constance; Thomas, Shibu; Santiago-Walker, Ademi; Triantos, Spyros; Sweiti, Hussein; Loriot, Yohann; Greco, Martin Alberto; Coward, Jim; Joshua, Anthony; Karapetis, Christos; Hart, Christopher; Zhang, Alison; Prenen, Hans; Goeminne, Jean-Charles; Machiels, Jean-Pascal; Rottey, Sylvie; Corassa, Marcelo; Molin, Graziela Zibetti Dal; Tiscoski, Katsuki; Jardim, Denis Leonardo Fontes; Mak, Milena; Fu, Wei; Yao, Herui; Huang, Jing; Jiang, Haiping; Chen, Baoshi; Yan, Dong; Yang, Yu; Le Tourneau, Christophe; Penel, Nicolas; Salas, Sébastien; Blay, Jean-Yves; Brachet, Pierre-Emmanuel; Durando, Xavier; Emambux, Sheik; Ravaud, Alain; Folprecht, Gunnar; Ahrens, Marit; Golf, Alexander; Haag, Georg Martin; Lordick, Florian; Desuki, Alexander; Cazzaniga, Marina; Ciardiello, Fortunato; Milella, Michele; Koyama, Takafumi; Hirooka, Yoshiki; Okamoto, Wataru; Aogi, Kenjiro; Kuboki, Yasutoshi; Lee, Jungyun; Kim, Sung-Bae; Ahn, Myung-Ju; Chang, Jong Hee; Kim, Yong-Man; Nam, Do-Hyun; Park, Jae-Sung; Paz-Ares, Luis; Moreno, Victor; Cervantes, Andres; Calvo, Mariona; Falcon, Alejandro; Gonzalez, Antonio; Martinez Bueno, Alejandro; García-Corbacho, Javier; Longo, Federico; Yen, Chia-Jui; Chen, Jen-Shi; Hou, Ming-Feng; Chao, Yee; Rau, Kun-Ming; Chiu, Tai-Jan; Feng, Yin-Hsun; Hsu, Chih-Hung; Huang, Wen-Tsung; Lai, Kuan-Ming; Yeh, Su-peng; Palmer, Daniel; Welsh, Liam; Plummer, Ruth; Iyer, Gopakumar; Bilen, Mehmet; Arrowsmith, Edward; Spigel, David Robert; Zandberg, Dan Paul; Doroshow, Deborah; Lu-Emerson, Christine; Moezi, Mehdi; Paulson, Scott; Ward, Patrick; Chaves, Jorge; Grigg, Claud; Hussein, Atif; Manda, Sudhir; Monticelli, Michael; Qamar, Rubina; Richey, Stephen L; Tamura, David; Wilks, Sharon
    Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR) : An international, single-arm, phase 2 study
    In: The Lancet Oncology Vol. 24 (2023) Nr. 8, pp. 925 - 935
  • Strickler, John H.; Satake, Hironaga; George, Thomas J.; Yaeger, Rona; Hollebecque, Antoine; Garrido-Laguna, Ignacio; Schuler, Martin; Burns, Timothy F.; Coveler, Andrew L.; Falchook, Gerald S.; Vincent, Mark; Sunakawa, Yu; Dahan, Laetitia; Bajor, David; Rha, Sun-Young; Lemech, Charlotte; Juric, Dejan; Rehn, Marko; Ngarmchamnanrith, Gataree; Jafarinasabian, Pegah; Tran, Qui; Hong, David S.
    Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
    In: The New England Journal of Medicine Vol. 388 (2023) Nr. 1, pp. 33 - 43
  • Schuler, Martin; Zimmer, Lisa; Kim, Kevin B.; Sosman, Jeffrey A.; Ascierto, Paolo A.; Postow, Michael A.; De Vos, Filip Y.F.L.; van Herpen, Carla M.L.; Carlino, Matteo S.; Johnson, Douglas B.; Berking, Carola; Reddy, Micaela B.; Harney, Allison S.; Berlin, Jordan D.; Amaria, Rodabe N.
    Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
    In: Clinical Cancer Research Vol. 28 (2022) Nr. 14, pp. 3002 - 3010
  • Krebs, Matthew G.; Malapelle, Umberto; André, Fabrice; Paz-Ares, Luis; Schuler, Martin; Thomas, David M.; Vainer, Gilad; Yoshino, Takayuki; Rolfo, Christian
    Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
    In: JAMA Oncology Vol. 8 (2022) Nr. 12, pp. 1830 - 1839
  • Fendler, Wolfgang; Pabst, Kim M.; Kessler, Lukas; Fragoso Costa, Pedro; Ferdinandus, Justin; Weber, Manuel; Lippert, Maria; Lückerath, Katharina; Umutlu, Lale; Kostbade, Karina; Mavroeidi, Ilektra A.; Schuler, Martin; Ahrens, Marit; Rischpler, Christoph; Bauer, Sebastian; Herrmann, Ken; Siveke, Jens; Hamacher, Rainer
    Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
    In: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4346 - 4353
  • Schuler, Martin
    Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – The next generation”
    In: Annals of Oncology Vol. 32 (2021) Nr. 1, pp. 126
  • Şahin, Uǧur; Türeci, Özlem; Manikhas, Georgiy Moiseevich; Lordick, Florian; Rusyn, Andrii; Vynnychenko, Ihor A.; Dudov, Asen; Bazin, Igor S.; Bondarenko, Igor; Melichar, Bohuslav; Dhaene, Karl F.L.; Wiechen, Kai; Huber, Claudia; Maurus, Daniel; Arozullah, A.; Park, J.W.; Schuler, Martin; Al-Batran, Salah Eddin
    FAST : a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
    In: Annals of Oncology Vol. 32 (2021) Nr. 5, pp. 609 - 619
  • Wick, Antje; Bahr, Oliver; Schuler, Martin; Rohrberg, Kristoffer; Chawla, Sant P.; Janku, Filip; Schiff, David; Heinemann, Volker; Narita, Yoshitaka; Lenz, Heinz-Josef; Ikeda, Masafumi; Ando, Yuichi; Wick, Wolfgang; Steinbach, Joachim P.; Burger, Michael C.; Wenger, Katharina; Lassen, Ulrik; Sankhala, Kamalesh K.; Roggia, Cristiana; Genvresse, Isabelle; Munhoz, Catya; Rentzsch, Christine; Reschke, Susanne; Langer, Simon; Wagner, Markus; Kaulfuss, Stefan; Cai, Charles; Lagkadinou, Eleni; Jeffers, Michael; Peña, Carol; Tabatabai, Ghazaleh
    Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors
    In: Clinical Cancer Research Vol. 27 (2021) Nr. 10, pp. 2723 - 2733
  • Skoulidis, Ferdinandos; Li, Bob T.; Dy, Grace K.; Price, Timothy J.; Falchook, Gerald S.; Wolf, Jürgen; Italiano, Antoine; Schuler, Martin; Borghaei, Hossein; Barlesi, Fabrice; Kato, Terufumi; Curioni-Fontecedro, Alessandra; Sacher, Adrian; Spira, Alexander; Ramalingam, Suresh S.; Takahashi, Toshiaki; Besse, Benjamin; Anderson, Abraham; Ang, Agnes; Tran, Qui; Mather, Omar; Henary, Haby; Ngarmchamnanrith, Gataree; Friberg, Gregory; Velcheti, Vamsidhar; Govindan, Ramaswamy
    Sotorasib for Lung Cancers with KRAS p.G12C Mutation
    In: The New England Journal of Medicine Vol. 384 (2021) Nr. 25, pp. 2371 - 2381
  • Wiesweg, Marcel; Schuler, Martin; Schildhaus, Hans-Ulrich
    Crizotinib in ROS1 and MET deregulated NSCLC-letter
    In: Clinical Cancer Research Vol. 26 (2020) Nr. 7, pp. 1774
  • Schuler, Martin; Berardi, Rossana; Lim, Darren Wan Teck; de Jonge, Maja J. A.; Bauer, Todd M.; Azaro, Analía; Gottfried, Maya; Han, Jiyoun; Lee, Dae-hee; Wollner, M.; Hong, David S.; Vogel, Arndt; Delmonte, Angelo; Akimov, Mikhail; Ghebremariam, Samson; Cui, X.; Nwana, N.; Giovannini, Monica; Kim, Tae-min
    Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : Clinical and biomarker results from a phase I trial
    In: Annals of Oncology Vol. 31 (2020) Nr. 6, pp. 789 - 797
  • Schuler, Martin
    The quest for efficient trial designs in precision oncology
    In: The Lancet Oncology Vol. 21 (2020) Nr. 12, pp. 1539 - 1541
  • Türeci, Özlem; Sahin, Ugur; Schulze-Bergkamen, Henning; Zvirbule, Zanete; Lordick, Florian; Koeberle, Dieter; Thuss-Patience, Peter C.; Ettrich, Thomas J.; Arnold, Dirk; Bassermann, Florian; Al-Batran, Salah Eddin; Wiechen, K.; Dhaene, Karl F. L.; Maurus, D.; Gold, M.; Huber, Christopher H.; Krivoshik, Andrew P.; Arozullah, A.; Park, J. W.; Schuler, Martin
    A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus : the MONO study
    In: Annals of Oncology Vol. 30 (2019) Nr. 9, pp. 1487 - 1495
  • Juric, Dejan; Janku, Filip; Rodón, Jordi; Burris, Howard A.; Mayer, Ingrid A.; Schuler, Martin; Seggewiss-Bernhardt, Ruth; Gil-Martin, Marta; Middleton, Mark R.; Baselga, José; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Schumacher, Karl; Huang, Alan; Quadt, Cornelia; Rugo, Hope S.
    Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer : A Phase 1b Clinical Trial
    In: JAMA Oncology Vol. 5 (2019) Nr. 2, pp. e184475
  • Wiesweg, Marcel; Mairinger, Fabian; Reis, Henning; Goetz, Moritz; Walter, Robert; Hager, Thomas; Metzenmacher, Martin; Eberhardt, Wilfried; McCutcheon, A.; Köster, J.; Stuschke, Martin; Aigner, Clemens; Darwiche, Kaid; Schmid, Kurt Werner; Rahmann, Sven; Schuler, Martin
    Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer
    In: Annals of Oncology Vol. 30 (2019) Nr. 4, pp. 655 - 657
  • Schuler, Martin; Cho, Byoung Chul; Sayehli, Cyrus Michael; Navarro, Alejandro; Soo, Ross A.; Richly, Heike; Cassier, Philippe Alexandre; Tai, David; Penel, Nicolas; Nogova, Lucia; Park, Se Hoon; Schostak, Martin; Gajate, Pablo; Cathomas, Richard; Rajagopalan, Prabhu; Grevel, Joachim; Bender, Sebastian; Boix, Oliver; Nogai, Hendrik; Ocker, Matthias; Ellinghaus, Peter; Joerger, Markus
    Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression : a phase 1 dose-escalation and dose-expansion study
    In: The Lancet Oncology Vol. 20 (2019) Nr. 10, pp. 1454 - 1466
  • Grünwald, Viktor; Schuler, Martin H.; Schöffski, Patrick; Kopp, Hans-Georg; Bauer, Sebastian; Kasper, Bernd; Lindner, Lars H.; Chemnitz, Jens M.; Crysandt, Martina; Stein, Alexander; Steffen, B.; Richter, Stephan; Kneba, Michael; Egerer, Gerlinde; Zimmermann, S.; Karch, Annika; Kunitz, Annegret
    Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line
    In: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii577
  • Joerger, M.; Soo, R. A.; Cho, B. C.; Navarro, A.; Sayehli, C. M.; Richly, Heike; Tai, D.; Kim, D. W.; Wolf, J.; Cassier, P.; Bender, S.; Ellinghaus, P.; Ince, S.; Rajagopalan, P.; Ocker, M.; Schuler, Martin
    A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors : Results from rogaratinib Phase-1 study
    In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
  • Al-Batran, S. E.; Pauligk, C.; Homann, N.; Schmalenberg, H.; Kopp, H. G.; Haag, G. M.; Luley, K.; Folprecht, G.; Probst, S.; Thuss-Patience, P.; Trojan, J.; Koenigsmann, M.; Lindig, U.; Pohl, M.; Kasper, Stefan; Hler, M. M.; Goetze, T.; Schuler, Martin; Jaeger, E.; Hofheinz, R. D.
    Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer : Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
    In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
  • Schuler, Martin; Paz-Ares, L.; Sequist, L. V.; Wu, Y. L.; Geater, S. L.; Marten, A.; Fandrey, Joachim; Park, K.; Yang, JCH
    First-line afatinib for advanced EGFRm1 NSCLC : Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials
    In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 2,
  • Guberina, M.; Eberhardt, Wilfried; Stuschke, Martin; Gauler, Thomas; Heinzelmann, F.; Cheufou, D.; Kimmich, M.; Friedel, G.; Schmidberger, H.; Darwiche, Kaid; Jendrossek, Verena; Schuler, Martin; Stamatis, Georgios; Pöttgen, Christoph
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer : secondary analysis of a randomized trial
    In: Annals of Oncology Vol. 28 (2017) Nr. 5, pp. 1084 - 1089
  • Okimoto, Ross A; Breitenbücher, Frank; Olivas, Victor R; Wu, Wei; Gini, Beatrice; Hofree, Matan; Asthana, Saurabh; Hrustanovic, Gorjan; Flanagan, Jennifer; Tulpule, Asmin; Blakely, Collin M; Haringsma, Henry J; Simmons, Andrew D; Gowen, Kyle; Suh, James; Miller, Vincent A; Ali, Siraj; Schuler, Martin; Bivona, Trever G.
    Inactivation of Capicua drives cancer metastasis
    In: Nature Genetics Vol. 49 (2017) Nr. 1, pp. 87 - 96
  • Kalkavan, Halime; Sharma, Piyush; Kasper, Stefan; Helfrich, Iris; Pandyra, Aleksandra A.; Gassa, Asmae; Virchow, Isabel; Flatz, Lukas; Brandenburg, Tim; Namineni, Sukumar; Heikenwalder, Mathias; Höchst, Bastian; Knolle, Percy A.; Wollmann, Guido; Von Laer, Dorothee; Drexler, Ingo; Rathbun, Jessica; Cannon, Paula M.; Scheu, Stefanie; Bauer, Jens; Chauhan, Jagat; Häussinger, Dieter; Willimsky, Gerald; Löhning, Max; Schadendorf, Dirk; Brandau, Sven; Schuler, Martin; Lang, Philipp A.; Lang, Karl S.
    Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regression
    In: Nature Communications Vol. 8 (2017) pp. 14447
  • Sequist, L.; Wu, Y. L.; Schuler, Martin; Kato, T.; Yang, JCH; Tanaka, H.; Hida, T.; Lu, S.; Park, K.; Laurie, S.; Bennouna, J.; Sibilot, D. M.; Marten, A.; Peil, B.; Ehrnrooth, E.; Yamamoto, N.; Nakagawa, K.
    Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7
    In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
  • Cappuzzo, Federico; Soo, Ross Andrew; Hochmair, Maximilian Johannes; Schuler, Martin; Mok, Tony Shu Kam; Stehle, Gerd; Cseh, Agnieszka; Lorence, Robert M..; Linden, Stephan; Forman, Nicole D.; Tsai, Chunming
    1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)
    In: Annals of Oncology Vol. 27 (2016) Nr. Supplement 6, pp. vi427
  • Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S W; Felip, Enriqueta; Chow, Laura Q M; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Jürgen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Sutradhar, Santosh; Li, Siyu; Szczudlo, Tomasz; Yovine, Alejandro; Shaw, Alice T
    Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1) : updated results from the multicentre, open-label, phase 1 trial
    In: The Lancet Oncology Vol. 17 (2016) Nr. 4, pp. 452 - 463
  • Yang, J C-H; Park, K; Kim, J-H; Bennouna, J; Chen, Y-M; Chouaid, C; De Marinis, F; Feng, J-F; Grossi, F; Kim, D-W; Liu, X; Lu, S; Strausz, J; Vinnyk, Y; Wiewrodt, R; Zhou, C; Wang, B; Chand, V K; Planchard, D; Ignatius Ou, Sai Hong; Planchard, David; Park, Keunchil; Schuler, Martin; Yang, James; Chand, Vikram; Rohr, Klaus; Bagnes, Claudia; Martin, Claudio Marcelo; Recondo, Gonzalo; Zarba, Juan Jose; Blajman, Cesar; Richardet, Martín; McLachlan, Sue-Anne; Parente, Phillip; Underhill, Craig; Crombie, Catherine; Mainwaring, Paul; Greil, Richard; Humblet, Yves; Bustin, Frédérique; Carestia, Luciano; Galdermans, Danny; Lambrechts, Marc; Delval, Laetitia; Vercauter, Piet; Zhou, Caicun; Wang, Jin; Huang, Cheng; Lin, Xiaoyan; Wu, Yilong; Liu, Xiaoqing; Cheng, Ying; Qin, Shukui; Feng, Jifeng; Huang, Jianjin; Zhang, Yiping; Lu, Shun; Zereu, Manuela; Garicochea, Bernardo; Zadra, Cyntia Albuquerque; Riska, Henrik; Alanko, Tuomo; Cadranel, Jacques; Chouaid, Christos; Zalcman, Gérard; Sibilot, Denis Moro; Perol, Maurice; Planchard, David; Bennouna, Jaafar; Fournel, Pierre; Gervais, Radj; Rotarski, Maciej; Coudert, Bruno; Schuler, Martin; Thomas, Michael; Wehler, Thomas; Faehling, Martin; Keilholz, Ulrich; Laack, Eckart; von Pawel, Joachim; Huber, Rudolf; Dickgreber, Nicolas; Wiewrodt, Rainer; Mark, Zsuzsanna; Tehenes, Sandor; Strausz, Janos; Sarosi, Veronika; Prabhash, Kumar; Jain, Minish; Venkatesan, Srinivasan; Sharma, Lalit; Dadhich, Hemant; Nagarkar, Rajnish Vasant; Onn, Amir; Gottfried, Maya; Stemmer, Solomon; Migliorino, Maria Rita; Grossi, Francesco; Bidoli, Paolo; Bearz, Alessandra; Gridelli, Cesare; Milandri, Carlo; Platania, Marco; Ceresoli, Giovanni Luca; Cruciani, Giorgio; Delgado, Francisco Gutierrez; Gonzalez Perez, José Luis; Luna, Gabriela Alvarado; Baca, Othon Padilla; Aerts, J G J V; Stigt, J A; Dingemans, A M C; Herder, G J M; Gans, S J M; Salas Sánchez, Jorge Fernando; Alvarez Barreda, Renzo Luzgardo; Pantigoso, Wilbert Rodriguez; Palomino, Osbert Luis Mejia; Jaskiewicz, Piotr; Kazarnowicz, Andrzej; Serwatowski, Piotr; Szczesna, Aleksandra; Jassem, Jacek; Lubennikov, Vladimir; Karaseva, Nina; Orlov, Sergey; Ragulin, Yuri; Garrido, Pilar; González Larriba, José Luis; Camps, Carlos; Campelo, Rosario García; Lianes, Pilar; Cobo, Manuel; Felip, Enriqueta; Kim, Dong-Wan; Kim, Sang-We; Park, Keunchil; Kim, Joo-Hang; Han, Ji-Youn; Kim, Young-Chul; Yang, Chih-Hsin; Hsia, Te-Chun; Chen, Yuh-Min; Tsai, Ying-Huang; Chang, Gee-Chen; Tsao, Thomas Chang-Yao; Su, Wu-Chou; Huang, Ming-Shyan; Ho, Ching-Liang; Hsieh, Ruey-Kuen; Vinnyk, Yuriy; Popovych, Oleksandr; Ponomarova, Olga; Bondarenko, Igor; Polishchuk, Iryna; Shah, Riyaz; Mitra, Sanka; Popat, Sanjaykumar; Spicer, James; Toy, Elizabeth; Popat, Sanjaykumar; Talbot, Toby; Brown, Emma; Upadhyay, Sunil; Summers, Yvonne; Gurtler, Jayne; Meza, Luis; Thropay, John
    Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib : phase III randomized LUX-Lung 5 trial
    In: Annals of Oncology Vol. 27 (2016) Nr. 3, pp. 417 - 423
  • Reimer, P.; Höhler, T.; Schuler, Martin; Markus, P.; Knipp, Heike; Schumacher, B.; Dechene, Alexander; Ting, Saskia; Kasper, S.; Meiler, Johannes; Kostbade, K.; Berger, W.; Herold, T.; Trarbach, Tanja; Linden, G.; Steinmetz, H.T.; Schmid, Kurt Werner; Worm, K.; Paul, A.
    Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial
    In: Annals of Oncology Vol. 27 (2016) Nr. Suppl.6, pp. 508P
  • Tabernero, J.; van Geel, R.; Guren, T.; Yaeger, R.; Spreafico, A.; Faris, J.; Yoshino, T.; Yamada, Y.; Tae, W. K.; Bendell, J.; Schuler, Martin; Lenz, H. J.; Eskens, F.; Desai, J.; Hochster, H.; Avsar, E.; Demuth, T.; Sandor, V.; Elez, E.; Schellens, J.
    Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC) : phase 2 results
    In: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 2, pp. ii127 - ii128
  • Yang, J C-H; Sequist, L V; Zhou, C; Schuler, Martin; Geater, S L; Mok, T; Hu, C-P; Yamamoto, N; Feng, J; O'Byrne, K; Lu, S; Hirsh, V; Huang, Y; Sebastian, M; Okamoto, I; Dickgreber, N; Shah, R; Märten, A; Massey, D; Wind, S; Wu, Y-L
    Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma : post hoc analyses of the randomized LUX-Lung 3 and 6 trials
    In: Annals of Oncology Vol. 27 (2016) Nr. 11, pp. 2103 - 2110
  • Al-Batran, Salah-Eddin; Hofheinz, Ralf D; Pauligk, Claudia; Kopp, Hans-Georg; Haag, Georg Martin; Luley, Kim Barbara; Meiler, Johannes; Homann, Nils; Lorenzen, Sylvie; Schmalenberg, Harald; Probst, Stephan; Koenigsmann, Michael; Egger, Matthias; Prasnikar, Nicole; Caca, Karel; Trojan, Jörg; Martens, Uwe M; Block, Andreas; Fischbach, Wolfgang; Mahlberg, Rolf; Clemens, Michael; Illerhaus, Gerald; Zirlik, Katja; Behringer, Dirk M; Schmiegel, Wolff; Pohl, Michael; Heike, Michael; Ronellenfitsch, Ulrich; Schuler, Martin; Bechstein, Wolf O; Königsrainer, Alfred; Gaiser, Timo; Schirmacher, Peter; Hozaeel, Wael; Reichart, Alexander; Goetze, Thorsten O; Sievert, Mark; Jäger, Elke; Mönig, Stefan; Tannapfel, Andrea
    Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO
    In: The Lancet Oncology Vol. 17 (2016) Nr. 12, pp. 1697 - 1708
  • Al-Batran, S. E.; Schuler, Martin; Zvirbule, Z.; Manikhas, G.; Lordick, F.; Tureci, O.; Huber, C.; Sahin, U.
    IMAB362 : a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer
    In: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 2, pp. ii141 - ii142
  • Schuler, Martin; Yang, J. C.-H.; Planchard, D.
    Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by Addeo
    In: Annals of Oncology Vol. 27 (2016) Nr. 6, pp. 1172 - 1173
  • Joerger, M.; Soo, R.; Cho, B.C.; Mendivil, A. Navarro; Sayehli, C.; Richly, Heike; Tai, D.; Kim, D.-W.; Wolf, J.; Cassier, P.; Ellinghaus, P.; Hildebrandt, S.; Behre, S.; Helmbrecht, C.; Kerpen, S.; Zielinski, D.; Ince, S.; Rajagopalan, P.; Ocker, M.; Schuler, Martin
    developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels
    In: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, 360O_PR
  • Wu, Y. L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, Martin; Hirsh, V.; Yamamoto, N.; OByrne, K.; Mok, T.; Massey, D.; Marten, A.; Yang, J. C. H.
    Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years : Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    In: Annals of Oncology Vol. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, pp. 136 - 137
  • Schuler, Martin; Yang, J. C. H.; Park, K.; Chand, V. K.; Wang, B.; Planchard, D.
    Afatinib (a) plus paclitaxel (p) following progression on a monotherapy in patients (pts) with metastatic non-small-cell lung cancer (nsclc) who previously benefited from erlotinib (e)/gefitinib (g) : a global randomised phase iii triallux-lung 5 (ll5)
    In: Annals of Oncology Vol. 26 (2015) Nr. S 1, pp. i33 - i34
  • Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova, Vera; Hirsh, Vera; Bennouna, Jaafar; Orlov, Sergey; Mok, Tony; Boyer, Michael; Su, Wu-Chou; Lee, Ki Hyeong; Kato, Terufumi; Massey, Dan; Shahidi, Mehdi; Zazulina, Victoria; Sequist, Lecia V
    Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trials
    In: The Lancet Oncology Vol. 16 (2015) Nr. 2, pp. 141 - 151
  • Yang, James C.-H.; Sequist, Lecia V.; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I.; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long
    Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations : A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    In: The Lancet Oncology Vol. 16 (2015) Nr. 7, pp. 830 - 838
  • George, Julie; Lim, Jing Shan; Jang, Se Jin; Cun, Yupeng; Ozretia, Luka; Kong, Gu; Leenders, Frauke; Lu, Xin; Fernández-Cuesta, Lynnette; Bosco, Graziella; Müller, Christian; Dahmen, Ilona; Jahchan, Nadine S.; Park, Kwon-Sik; Yang, Dian; Karnezis, Anthony N.; Vaka, Dedeepya; Torres, Angela; Wang, Maia Segura; Korbel, Jan O.; Menon, Roopika; Chun, Sung-Min; Kim, Deokhoon; Wilkerson, Matt; Hayes, Neil; Engelmann, David; Pützer, Brigitte; Bos, Marc; Michels, Sebastian; Vlasic, Ignacija; Seidel, Danila; Pinther, Berit; Schaub, Philipp; Becker, Christian; Altmüller, Janine; Yokota, Jun; Kohno, Takashi; Iwakawa, Reika; Tsuta, Koji; Noguchi, Masayuki; Muley, Thomas; Hoffmann, Hans; Schnabel, Philipp A.; Petersen, Iver; Chen, Yuan; Soltermann, Alex; Tischler, Verena; Choi, Chang-Min; Kim, Yong-Hee; Massion, Pierre P.; Zou, Yong; Jovanovic, Dragana; Kontic, Milica; Wright, Gavin M.; Russell, Prudence A.; Solomon, Benjamin; Koch, Ina; Lindner, Michael; Muscarella, Lucia A.; La Torre, Annamaria; Field, John K.; Jakopovic, Marko; Knezevic, Jelena; Castaños-Vélez, Esmeralda; Roz, Luca; Pastorino, Ugo; Brustugun, Odd-Terje; Lund-Iversen, Marius; Thunnissen, Erik; Köhler, Jens; Schuler, Martin; Botling, Johan; Sandelin, Martin; Sanchez-Cespedes, Montserrat; Salvesen, Helga B.; Achter, Viktor; Lang, Ulrich; Bogus, Magdalena; Schneider, Peter M.; Zander, Thomas; Ansén, Sascha; Hallek, Michael; Wolf, Jürgen; Vingron, Martin; Yatabe, Yasushi; Travis, William D.; Nürnberg, Peter; Reinhardt, Christian; Perner, Sven; Heukamp, Lukas; Büttner, Reinhard; Haas, Stefan A.; Brambilla, Elisabeth; Peifer, Martin; Sage, Julien; Thomas, Roman K.
    Comprehensive genomic profiles of small cell lung cancer
    In: Nature Vol. 524 (2015) Nr. 7563, pp. 47 - 53
  • Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; OByrne, K.; Okamoto, I.; Schuler, Martin; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Marten, A.; Wind, S.; Carbone, D. P.
    Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    In: Annals of Oncology Vol. 26 (2015) Nr. S 6, pp. vi73 - vi89
  • Wu, Y. L.; Sequist, L. V.; Schuler, Martin; Yamamoto, N.; Zhou, C.; Hu, C. P.; OByrne, K.; Hirsh, V.; Mok, T.; Zazulina, V.; Yang, J. C. H.
    Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut) : Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    In: Annals of Oncology Vol. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, pp. 136
  • Gautschi, Oliver; Bluthgen, Marie-Virginia; Smit, Egbert F.; Wolf, Jürgen; Früh, Martin; Petersenn, Stephan; Schuler, Martin; Zalcman, Gérard; Milia, Julie; Mazieres, Julien
    Targeted Therapy for Patients with BRAF-Mutant Lung Cancer : Results from the European EURAF Cohort
    In: Annals of Oncology Vol. 26 (2015) Nr. S 1: European Lung Cancer Conference (ELCC), Geneva, Switzerland, 15-18 April 2015 : Abstracts, pp. i61
  • Hyman, David M.; Puzanov, Igor; Subbiah, Vivek; Faris, Jason E.; Chau, Ian; Blay, Jean‑Yves; Wolf, Jürgen; Raje, Noopur S.; Diamond, Eli L.; Hollebecque, Antoine; Gervais, Radj; Elez‑Fernandez, Maria Elena; Italiano, Antoine; Hofheinz, Ralf‑Dieter; Hidalgo, Manuel; Chan, Emily; Schuler, Martin; Lasserre, Susan Frances; Makrutzki, Martina; Sirzen, Florin; Veronese, Maria Luisa; Tabernero, Josep; Baselga, José
    Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
    In: The New England Journal of Medicine Vol. 373 (2015) Nr. 8, pp. 726 - 736
  • Shaw, Alice T; Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S W; Felip, Enriqueta; Chow, Laura Q M; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Lau, Yvonne Y; Goldwasser, Meredith; Boral, Anthony L; Engelman, Jeffrey A
    Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
    In: The New England Journal of Medicine Vol. 370 (2014) Nr. 13, pp. 1189 - 1197
  • Yang, J. C.; Schuler, Martin; Yamamoto, N.; OByrne, K. J.; Hirsh, V.; Mok, TSK; Massey, D.; Zazulina, V.; Shahidi, M.; Sequist, L. V.
    Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in Lux-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed EGFR mutation-positive lung cancer
    In: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 410 - 411
  • Sequist, L. V.; Schuler, Martin; Yamamoto, N.; OByrne, K. J.; Hirsh, V.; Mok, TSK; Lungershausen, J.; Shahidi, M.; Palmer, M.; Yang, J. C.
    LUX-Lung 3 : Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations
    In: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 402
  • Yamamoto, N.; Schuler, Martin; OByrne, K.; Hirsh, V.; Mok, T.; Kato, T.; Yoshioka, H.; Okamoto, I.; Yokoyama, A.; Massey, D.; Jones, H.; Zazulina, V.; Shahidi, M.; Sequist, L.; Yang, JCH
    Lux-LungG 3 : Afatinib versus cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harboring an EGFR mutation
    In: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 11, pp. 8
  • Dirix, L.; Schuler, Martin; Machiels, J.; Hess, D.; Awada, A.; Steeghs, N.; Paz-Ares, L.; von Moos, R.; Rabault, B.; Rodon, J.
    Phase IB dose-escalation study of BEZ235 or BKM 120 in combination with paclitaxel (PTX) in patients with advanced solid tumors
    In: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 157 - 158
  • Schmidt, Markus; Rüttinger, Dominik; Sebastian, M.; Hanusch, Claus A.; Marschner, Norbert; Bäuerle, Patrick A.; Wolf, Andreas; Göppel, Gertrud; Oruzio, Daniel; Schlimok, Günter; Steger, Günther G.; Wolf, Christopher; Eiermann, Wolfgang; Lang, Alois; Schuler, Martin
    Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast cancer
    In: Annals of Oncology Vol. 23 (2012) Nr. 9, pp. 2306 - 2313
  • Schmidt, Martina; Scheulen, Max Ernst; Dittrich, C.; Obrist, P.; Marschner, N.; Dirix, L.; Schmidt, M.; Rüttinger, D.; Schuler, Martin; Reinhardt, C.; Awada, A.
    An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
    In: Annals of Oncology Vol. 21 (2010) Nr. 2, pp. 275 - 282
  • Petry, I. B.; Fieber, E.; Schmidt, Marcus; Gehrmann, M.; Gebhard, S.; Hermes, M.; Schormann, W.; Selinski, S.; Freis, E.; Schwender, H.; Brulport, M.; Ickstadt, K.; Rahnenführer, J.; Maccoux, L.; West, J.; Kölbl, H.; Schuler, Martin; Hengstler, J. G.
    ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer
    In: Clinical Cancer Research Vol. 16 (2010) Nr. 2, pp. 451 - 460